Genomic Markers Can Predict Lynch Syndrome Across Tumor Types
Researchers from Memorial Sloan Kettering Cancer Center found that genomic markers can predict Lynch Syndrome across tumor types suggesting Lynch Syndrome is linked to more types of cancer than previously thought. This data suggests that all individuals with MSI-H (high microsatellite instability) tumors be tested for Lynch Syndrome. The benefit of early detection of Lynch Syndrome extends beyond the individual with cancer, as family members could benefit with the goal of early detection or even cancer prevention.